🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against superbug strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting more than 82 million infections annually. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which involves two antibiotics. The study included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced positive views. Access to a one-pill regimen such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to reduce the burden of the disease for patients and to prevent the spread of extremely resistant gonorrhoea globally.